MX2012003042A - Uso de guaifenesina para inhibir la secrecion de mucina. - Google Patents

Uso de guaifenesina para inhibir la secrecion de mucina.

Info

Publication number
MX2012003042A
MX2012003042A MX2012003042A MX2012003042A MX2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A
Authority
MX
Mexico
Prior art keywords
guaifenesin
mucin secretion
inhibiting mucin
inhibiting
secretion
Prior art date
Application number
MX2012003042A
Other languages
English (en)
Spanish (es)
Inventor
Helmut Albrecht
Kim K Chul
Jeanclare Seagrave
Bruce K Rubin
Gail Solomon
Original Assignee
Reckitt Benckiser Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser Llc filed Critical Reckitt Benckiser Llc
Publication of MX2012003042A publication Critical patent/MX2012003042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012003042A 2009-09-12 2010-09-13 Uso de guaifenesina para inhibir la secrecion de mucina. MX2012003042A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (1)

Publication Number Publication Date
MX2012003042A true MX2012003042A (es) 2012-05-29

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003042A MX2012003042A (es) 2009-09-12 2010-09-13 Uso de guaifenesina para inhibir la secrecion de mucina.

Country Status (12)

Country Link
EP (1) EP2475360A1 (enExample)
JP (1) JP2013504554A (enExample)
KR (1) KR20120068889A (enExample)
CN (1) CN102596189A (enExample)
AU (1) AU2010294008B2 (enExample)
BR (1) BR112012005517A2 (enExample)
CA (1) CA2773611A1 (enExample)
MX (1) MX2012003042A (enExample)
MY (1) MY161187A (enExample)
RU (1) RU2012114323A (enExample)
WO (1) WO2011030163A1 (enExample)
ZA (1) ZA201201822B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1206995A1 (en) * 2012-04-06 2016-01-22 The Uab Research Foundation Methods for increasing cftr activity
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
EP1471872A2 (en) * 2002-02-04 2004-11-03 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
CN1835942A (zh) * 2003-06-19 2006-09-20 金纳莱公司 粘蛋白合成抑制剂
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Also Published As

Publication number Publication date
WO2011030163A1 (en) 2011-03-17
ZA201201822B (en) 2013-05-29
CN102596189A (zh) 2012-07-18
AU2010294008B2 (en) 2014-08-14
MY161187A (en) 2017-04-14
BR112012005517A2 (pt) 2016-04-19
CA2773611A1 (en) 2011-03-17
KR20120068889A (ko) 2012-06-27
AU2010294008A1 (en) 2012-04-05
EP2475360A1 (en) 2012-07-18
JP2013504554A (ja) 2013-02-07
RU2012114323A (ru) 2013-10-20

Similar Documents

Publication Publication Date Title
GB2469580B (en) Delivery method and compositions
EP2231133A4 (en) METHOD AND COMPOSITION FOR THE ADMINISTRATION OF RESVERATROL AND PTEROSTILS
IL216374A0 (en) Compositions and methods for drug delivery
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
PT2512236T (pt) Método aperfeiçoado de administração de beta-hidroxi-beta-metilbutirato (hmb)
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
IL216383A0 (en) Compositions for continuous administration of dopa decarboxylase inhibitors
EP2442655A4 (en) COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP2470019A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS
PL2385029T3 (pl) Kompozycje i sposób cementowania odwiertów
IN2014CN04634A (enExample)
IL216993A0 (en) Compositions and methods for treatment of multiple sclerosis
PL2421545T3 (pl) Sposób i kompozycja do synchronizacji czasu inseminacji
ZA201203012B (en) Solid pharmaceutical compositions containing an intergrase inhibitor
EP2588132A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
PT2496225T (pt) Inibidores de esfingosina do tipo i e processos para os produzir e utilizar
ZA201203060B (en) Composition and method of delivery
ZA201104670B (en) Pharmaceutical composition comprising aleglitazar
SG10201907649QA (en) Preventive or therapeutic agent for fibrosis
IL213105A0 (en) Dipeptidyl peptidase iv inhibitors
IL213955A (en) Method for improved biological activity of pharmaceutical preparations
EP2501390A4 (en) COMPOSITIONS AND METHODS OF ACTIVITY ON CYTOKINS AND NF-KB
MY161187A (en) Use of guaifenesin for inhibiting mucin secretion
EP2651429A4 (en) NEUROPEPTIDE ANALOGUES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
ZA201400653B (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation